Drugs / alvocidib
last change Aug 2021 re-read 2 minutes ago

alvocidib

Small molecule targets CDK1, CDK2, CDK4, CDK6, CDK7, CDK9 via inhibition

Developed for
cancer of unknown primary site · acute myeloid leukemia · chronic lymphocytic leukemia/small lymphocytic lymphoma · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with minimal differentiation · acute myeloid leukemia with t(8;21)(q22;q22) translocation
+81 more · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute myelomonocytic leukemia M4 · adult acute monocytic leukemia · acute erythroid leukemia · acute megakaryoblastic leukemia in adult · adult acute lymphoblastic leukemia · lymphoma · Waldenstrom macroglobulinemia · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia, inv(16)(p13.1;q22) · MALT lymphoma · mantle cell lymphoma · nodal marginal zone B-cell lymphoma · plasma cell myeloma · prolymphocytic leukemia · prostate cancer · splenic marginal zone lymphoma · acute basophilic leukemia · acute myeloid leukemia with multilineage dysplasia · acute myeloid leukemia, del(5q31-q32) · B-cell chronic lymphocytic leukemia · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · breast cancer · cutaneous melanoma · esophageal cancer · pancreatic adenocarcinoma · soft tissue sarcoma · adult nodular lymphocyte predominant Hodgkin lymphoma · adult T-cell leukemia/lymphoma · anaplastic large cell lymphoma · angioimmunoblastic T-cell lymphoma · Burkitt lymphoma · cerebellar astrocytoma · childhood brain stem glioma · childhood ependymoma · childhood kidney neoplasm · childhood medulloblastoma · diffuse gastric adenocarcinoma · diffuse large B-cell lymphoma · endometrial cancer · erythroleukemia · Ewing sarcoma/peripheral primitive neuroectodermal tumor · extragonadal nonseminomatous germ cell tumor · extragonadal seminoma · gastric intestinal type adenocarcinoma · gastroesophageal junction adenocarcinoma · gastrointestinal stromal tumor · grade III lymphomatoid granulomatosis · head and neck cancer · hematopoietic and lymphoid system neoplasm · HER2 positive breast carcinoma · Hodgkin's lymphoma, lymphocytic depletion · Hodgkin's lymphoma, mixed cellularity · Hodgkins lymphoma · leukemia · liver and intrahepatic bile duct neoplasm · liver cancer · male breast carcinoma · malignant childhood germ cell neoplasm · malignant epithelial tumor of ovary · malignant pleural mesothelioma · malignant testicular germ cell tumor · mycosis fungoides and variants · myelodysplastic syndrome · myelodysplastic syndrome with excess blasts · neuroblastoma · nodular sclerosis classical Hodgkin lymphoma · non-small cell lung carcinoma · optic pathway glioma · osteosarcoma · ovarian germ cell tumor · precursor lymphoblastic lymphoma/leukemia · primary peritoneal carcinoma · refractory hairy cell leukemia · refractory plasma cell neoplasm · renal cell carcinoma · retinoblastoma · rhabdomyosarcoma · small cell carcinoma · small intestine cancer · supratentorial primitive neuroectodermal tumor
Investigated by
National Cancer Institute (NCI) · Memorial Sloan Kettering Cancer Center · Sumitomo Pharma America, Inc. · NCIC Clinical Trials Group · AbbVie · Barbara Ann Karmanos Cancer Institute
+7 more · Gynecologic Oncology Group · M.D. Anderson Cancer Center · Mayo Clinic · SWOG Cancer Research Network · Sanofi · Sumitomo Pharma Co., Ltd. · Virginia Commonwealth University

Trials 64 · started per year

today
3
2
1
7
7
6
5
8
2
7
2
3
2
1
1
1
1
3
2
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 133 trials
Phase 1 NCT03441555 May 2018 → Jan 2021 acute myeloid leukemia AbbVie Completed No outcome recorded
Phase 1 NCT03563560 May 2018 → Mar 2020 acute myeloid leukemia Sumitomo Pharma Co., Ltd. Completed No outcome recorded
Phase 1 NCT03298984 Sep 2017 → Mar 2020 acute myeloid leukemia Sumitomo Pharma America, Inc. Completed No outcome recorded
Phase 1 NCT01076556 Apr → Jul 2010 chronic lymphocytic leukemia/small lymphocytic lymphoma, prolymphocytic leukemia National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1 NCT00735930 Aug 2008 → Mar 2013 anemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, prolymphocytic leukemia, thrombocytopenia National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00470197 Apr 2007 → Jan 2011 acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +8 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00377104 Sep 2006 → Nov 2012 chronic lymphocytic leukemia/small lymphocytic lymphoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1 NCT00324480 Mar 2006 → Apr 2009 cancer of unknown primary site National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00112684 Feb 2006 → Jul 2012 cancer of unknown primary site National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1 NCT00278330 Jan 2006 → Oct 2009 acute myeloid leukemia, adult acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, myelodysplastic syndrome with excess blasts National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/27 trials
Phase 1/2 NCT04493099 Oct 2020 acute myeloid leukemia M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 1/2 NCT03593915 Aug 2018 → Aug 2021 myelodysplastic syndrome Sumitomo Pharma America, Inc. Terminated No outcome recorded
Phase 1/2 NCT00445341 Nov 2006 → Apr 2012 lymphoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT00112723 Dec 2005 → Feb 2011 Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, mixed cellularity, MALT lymphoma, Waldenstrom macroglobulinemia +12 National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1/2 NCT00058240 Apr 2003 → Feb 2009 Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT00016016 Feb 2001 → Nov 2006 acute myeloid leukemia, adult acute lymphoblastic leukemia National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT00020332 Oct 2000 → Mar 2003 breast cancer National Cancer Institute (NCI) Completed No outcome recorded
Phase 224 trials
Phase 2 NCT03969420 Jan 2020 → Apr 2021 acute myeloid leukemia Sumitomo Pharma America, Inc. Terminated No outcome recorded
Phase 2 NCT02520011 Mar 2016 → Feb 2020 acute myeloid leukemia Sumitomo Pharma America, Inc. Terminated No outcome recorded
Phase 2 NCT01349972 Apr 2011 → May 2014 acute erythroid leukemia, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation, acute myeloid leukemia with 11q23 abnormalities +8 National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00991952 Sep 2009 → Feb 2012 diffuse gastric adenocarcinoma, gastric intestinal type adenocarcinoma, gastroesophageal junction adenocarcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00957905 Jun 2009 → Aug 2014 extragonadal nonseminomatous germ cell tumor, extragonadal seminoma, malignant testicular germ cell tumor, ovarian germ cell tumor National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00795002 Nov 2008 → Nov 2010 acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +9 National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00634244 Oct 2008 → Sep 2014 acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +7 National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00464633 Mar 2007 → Dec 2011 chronic lymphocytic leukemia/small lymphocytic lymphoma Sanofi Completed No outcome recorded
Phase 2 NCT00407966 Oct 2006 → Jul 2008 acute basophilic leukemia, acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation +8 National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00331682 Mar 2006 → May 2008 pancreatic adenocarcinoma National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 20 cited values

Every value below carries the sentence it was read from. 67 sources stand behind the page.

FieldValueCited text
Known as alvocidib “Flavopiridol (alvocidib)” NCT00094978
61

NCT00005971

NCT00058240

NCT00064285

NCT00101231

NCT00012181

NCT03563560

NCT00079352

NCT00006245

NCT03298984

NCT02520011

NCT00016185

NCT00047203

NCT00083122

NCT03593915

NCT00795002

NCT00042874

NCT00019344

NCT00470197

NCT03441555

NCT00047307

NCT00278330

NCT00080990

NCT00046917

NCT00006485

NCT00003039

NCT00003004

NCT00058227

NCT00003620

NCT00112684

NCT00016016

NCT00007917

NCT00324480

NCT00020332

NCT00991952

NCT00464633

NCT00005074

NCT01349972

NCT00072436

NCT00023894

NCT00045448

NCT00331682

NCT00098371

NCT00020189

NCT00377104

NCT00039455

NCT00003690

NCT00735930

NCT00070239

NCT00098579

NCT00957905

NCT00634244

NCT00003256

NCT00112723

NCT00082784

NCT00087282

NCT00005974

NCT00407966

NCT03969420

NCT01076556

NCT00016939

NCT00021073

Known as Alvocidib freebase ChEMBL registry synonym — accepted as the source's own label CHEMBL428690
Known as Alvocidib Hydrochloride ClinicalTrials.gov intervention name — accepted as the source's own label NCT04493099
Known as FLAVO “To determine a safe and tolerated dose of flavopiridol (alvocidib) in combination with standard dose rituximab and fludarabine” NCT00058227
Known as flavopiridol “Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms” NCT00082784
6

“A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin with or without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors” NCT00957905

“Drugs used in chemotherapy, such as irinotecan and flavopiridol, work in different ways to stop tumor cells from dividing so they stop growing or die.” NCT00087282

“To determine a safe and tolerated dose of flavopiridol (alvocidib) in combination with standard dose rituximab and fludarabine” NCT00058227

“Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection” NCT03969420

NCT00445341

NCT00094978

Known as Flavopiridol hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL428690
Known as HL 275 ChEMBL registry synonym — accepted as the source's own label CHEMBL428690
Known as HMR 1275 ChEMBL registry synonym — accepted as the source's own label CHEMBL428690
Known as L 86 8275 ChEMBL registry synonym — accepted as the source's own label CHEMBL428690
Known as MDL 107,826A ChEMBL registry synonym — accepted as the source's own label CHEMBL428690
Known as NSC 649890 “Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms” NCT00082784
Action Inhibit “the cyclin dependent kinase (cdk) inhibitor flavopiridol” PMID 15122079 Aug 2004
5

“Cyclin-dependent kinase 4 inhibitor” CHEMBL428690

“Cyclin-dependent kinase 7 inhibitor” CHEMBL428690

“Cyclin-dependent kinase 2 inhibitor” CHEMBL428690

“Cyclin-dependent kinase 6 inhibitor” CHEMBL428690

“Cyclin-dependent kinase 1 inhibitor” CHEMBL428690

Modality Small molecule “Flavopiridol is a synthetic N-methylpiperidinyl, chlorophenyl flavone compound” NCT00445341
1

CHEMBL428690

Route Intravenous “Given IV” NCT00003620
Target CDK1 “Cyclin-dependent kinase 1 inhibitor” CHEMBL428690
Target CDK2 “Cyclin-dependent kinase 2 inhibitor” CHEMBL428690
Target CDK4 “Cyclin-dependent kinase 4 inhibitor” CHEMBL428690
Target CDK6 “Cyclin-dependent kinase 6 inhibitor” CHEMBL428690
Target CDK7 “Cyclin-dependent kinase 7 inhibitor” CHEMBL428690
Target CDK9 “Alvocidib is a cyclin-dependent kinase 9 inhibitor leading to downregulation of the antiapoptotic BCL-2 family member, MCL-1.” PMID 32998965 Sep 2020